Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
rheumatic fever/fièvre
Le lien est enregistré dans le presse-papiers
9 résultats
Test for rheumatic fever and monoclonal antibodies useful therefor
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
This invention is concerned with monoclonal antibodies useful to detect humans who are susceptible to attacks of rheumatic fever. It is concerned also with methods of producing and using such antibodies, compositions containing them, hybridoma cell lines useful for
Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This application is a National Stage Application of International Application Number PCT/EP2007/004898, filed Jun. 1, 2007; which claims priority to European Patent Application No. 06011685.2, filed Jun. 6, 2006, all of which are incorporated herein in their entirety.
The present invention relates
Compound WS 727713
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
TECHNICAL FIELD
The present invention relates to a new compound which is useful as a medicament or a cosmetic, to a process for producing the same and to a pharmaceutical composition comprising the same.
BACKGROUND ART
The melanocortin (MC) is a group of peptide hormones that are derived from
Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
This invention relates to compounds and pharmaceutical compositions for the treatment of cyclooxygenase mediated diseases and methods of treating thereof.
Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and
Pharmaceutical composition for preventing / treating TRPV1 activity-related and inflammation-related diseases or conditions containing maillard peptide separated from well-aged traditional soy sauce as active ingredient
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 371 of PCT/KR2010/007845, filed Nov. 8, 2010, which claims the benefit of Korean Patent Application No. 10-2009-0106912, filed Nov. 6, 2009, the entire contents of each of which are incorporated herein by reference.
TECHNICAL FIELD
The
Vaccine against group A beta hemolytic streptococcus and respective process for obtaining thereof
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The Applicant already holds patent application PI 0501290-2, filed on Mar. 24, 2005, referring to a "VACCINE AGAINST GROUP A BETA HEMOLYTIC STREPTOCOCCUS AND RESPECTIVE PROCESS FOR OBTAINING THEREOF". This patent refers to a new vaccine whose purpose is the same, as well as a
Antigen of hybrid M protein and carrier for group A streptococcal vaccine
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF INVENTION
The present invention relates broadly to the field of recombinant vaccines. The vaccines are directed to preventing Group A streptococcal infections, which may otherwise result in rheumatic fever.
BACKGROUND OF THE INVENTION
Acute rheumatic fever (ARF) is the major cause of heart
Antigen of hybrid M protein and carrier for Group A streptococccal vaccine
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF INVENTION
The present invention relates broadly to the field of recombinant vaccines. The vaccines are directed to preventing Group A streptococcal infections, which may otherwise result in rheumatic fever.
BACKGROUND OF THE INVENTION
Acute rheumatic fever (ARF) is the major cause of heart
Recombinant multivalent M protein vaccine
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
The invention relates to recombinant multivalent M protein vaccines useful to control group A streptococcal infections of different serotypes which may result in rheumatic fever, rheumatic heart disease, and to other embodiments further described herein.
BACKGROUND OF THE
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
